Impact of early analgesia on hospitalization outcomes for sickle cell pain crisis

被引:13
|
作者
Payne, Jason [1 ]
Aban, Inmaculada [2 ]
Hilliard, Lee M. [1 ]
Madison, Jennifer [1 ]
Bemrich-Stolz, Christina [1 ]
Howard, Thomas H. [1 ]
Brandow, Amanda [3 ]
Waite, Emily [1 ]
Lebensburger, Jeffrey D. [1 ]
机构
[1] Univ Alabama Birmingham, Div Pediat Hematol Oncol, Birmingham, AL USA
[2] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA
[3] Med Coll Wisconsin, Div Pediat Hematol Oncol, Milwaukee, WI 53226 USA
关键词
outcomes; pain; sickle cell anemia; ACUTE-CARE UTILIZATION; EMERGENCY-DEPARTMENT; DISEASE; MANAGEMENT; ANEMIA; CHILDREN; FREQUENCY; EPISODES;
D O I
10.1002/pbc.27420
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Painful events are the leading cause of hospitalizations for patients with sickle cell disease. Individualized pain plans targeting patient-specific maximum opioid dosing may shorten hospitalization length and are recommended by national guidelines. Prior to implementing individualized sickle cell pain plans, we tested the hypothesis that a shorter time to achieve a maximum opioid dose would improve hospitalization outcomes. ProcedureResultsTwo-year IRB-approved, retrospective study of pediatric patients admitted for vaso-occlusive crisis (VOC). We recorded the emergency department admission time, order entry time for the maximum opioid dose during the hospitalization, and time of discharge orders. We categorized patients as infrequent if they required<3 admissions for VOC over two years and patients as frequent if they required 3 admissions for VOC over two years. To account for multiple admissions, generalized linear modeling was performed. We identified 236 admissions for acute pain observed in 108 patients. Achieving an earlier maximum opioid dose was significantly associated with shorter length of hospitalization for frequent and infrequent pain patients (both P 0.0001). As total hospitalization length can be impacted by the time a maximum opioid order was placed, we also analyzed hospitalization length after the maximum opioid order was placed. Frequent pain patients who achieved earlier analgesia had a significantly shorter hospitalization from the time the maximum opioid order was placed (P=0.03) while no association was found for infrequent pain patients (P=0.84). ConclusionsEarly achievement of maximum analgesia improved hospitalization outcomes and warrant further investigation in prospective studies of individualized pain plans.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Impact of Hydroxyurea Therapy in Reducing Pain Crises, Hospital Admissions, and Length of Stay Among Sickle Cell Patients in the Eastern Region of Saudi Arabia
    Albohassan, Hassan
    Ammen, Muhammed
    Alomran, Ali A.
    Shehab, Hussain Bu
    Al Sakkak, Hussain
    Al Bohassan, Afnan
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (11)
  • [42] Impact of Individualized Pain Plan on the Emergency Management of Children With Sickle Cell Disease
    Krishnamurti, Lakshmanan
    Smith-Packard, Bethanny
    Gupta, Ashish
    Campbell, Mary
    Gunawardena, Sriya
    Saladino, Richard
    PEDIATRIC BLOOD & CANCER, 2014, 61 (10) : 1747 - 1753
  • [43] EPIDURAL ANALGESIA IN THE MANAGEMENT OF SEVERE VASOOCCLUSIVE SICKLE-CELL CRISIS
    YASTER, M
    TOBIN, JR
    BILLETT, C
    CASELLA, JF
    DOVER, G
    PEDIATRICS, 1994, 93 (02) : 310 - 315
  • [44] Intraindividual pain variability and phenotypes of pain in sickle cell disease: a secondary analysis from the Pain in Sickle Cell Epidemiology Study
    Bakshi, Nitya
    Gillespie, Scott
    McClish, Donna
    McCracken, Courtney
    Smith, Wally R.
    Krishnamurti, Lakshmanan
    PAIN, 2022, 163 (06) : 1102 - 1113
  • [45] Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease
    Kang, Hyeun Ah
    Barner, Jamie C.
    Lawson, Kenneth A.
    Rascati, Karen
    Mignacca, Robert C.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (01) : 90 - 101
  • [46] Return visit rates after an emergency department discharge for children with sickle cell pain episodes
    Coleman, Keli D.
    McKinley, Kenneth
    Ellison, Angela M.
    Alpern, Elizabeth R.
    Hariharan, Selena
    Topoz, Irina
    Wurtz, Morgan
    Nielsen, Blake
    Cook, Lawrence J.
    Morris, Claudia R.
    Brandow, Amanda M.
    Campbell, Andrew D.
    Liem, Robert I.
    Nuss, Rachelle
    Quinn, Charles T.
    Thompson, Alexis A.
    Villella, Anthony
    King, Allison A.
    Baumann, Ana
    Frankenberger, Warren
    Brousseau, David C.
    PEDIATRIC BLOOD & CANCER, 2023, 70 (10)
  • [47] The Impact of a Multidisciplinary Pain Management Model on Sickle Cell Disease Pain Hospitalizations
    Brandow, Amanda M.
    Weisman, Steven J.
    Panepinto, Julie A.
    PEDIATRIC BLOOD & CANCER, 2011, 56 (05) : 789 - 793
  • [48] Impact of Imatinib on reducing the painful crisis in patients with sickle cell disease
    Karimi, Mojtaba
    Bahadoram, Mohammad
    Mafakher, Ladan
    Rastegar, Mohammadhossein
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2024, 46 (04) : 387 - 392
  • [49] Intravenous Magnesium for Pediatric Sickle Cell Vaso-Occlusive Crisis: Methodological Issues of a Randomized Controlled Trial
    Badaki-Makun, Oluwakemi
    Scott, J. Paul
    Panepinto, Julie A.
    Casper, T. Charles
    Hillery, Cheryl A.
    Dean, J. Michael
    Brousseau, David C.
    PEDIATRIC BLOOD & CANCER, 2014, 61 (06) : 1049 - 1054
  • [50] Benchmarking pain outcomes for children with sickle cell disease hospitalized in a tertiary referral pediatric hospital
    Vijenthira, Abi
    Stinson, Jennifer
    Friedman, Jeremy
    Palozzi, Lori
    Taddio, Anna
    Scolnik, Dennis
    Victor, Charles
    Kirby-Allen, Melanie
    Campbell, Fiona
    PAIN RESEARCH & MANAGEMENT, 2012, 17 (04) : 291 - 296